Skip to main content
. 2022 Apr 14;12(4):64. doi: 10.1038/s41408-022-00663-z

Fig. 1. Compound screen for Rac inhibitors.

Fig. 1

A virtual screen of Evotec’s library of commercially available compounds was performed that included an initial filtration for drug-like properties, followed by a preselection against shape-based pharmacophore of published RAC inhibitors. Next, a biological screen was carried out consisting of: (i) scoring for inhibition of growth on leukemic cell lines of 107 selected compounds, (ii) assessment of toxicity to normal bone marrow progenitors of compounds that showed good anti-leukemic activity, and (iii) validating on-target effects by RAC PBD pull down of non-toxic compounds. Created with BioRender.com.